Literature DB >> 14969682

The application of cryosurgery in the treatment of lung cancer.

M O Maiwand1, J M Evans, J E Beeson.   

Abstract

Lung cancer is the commonest cause of cancer death, with a very poor survival rate. By the time of diagnosis, most cases are at an advanced stage and about 30% present with symptoms caused by central endobronchial obstruction. Endobronchial cryosurgery is an effective technique, which can be used to relieve tracheobronchial obstruction caused by lung cancer. This report describes the technique, using a nitrous oxide cooled cryoprobe, inserted through a bronchoscope, to remove the obstruction and reopen the airway. In this study, 476 consecutive patients (mean age 68.3 years, M:F ratio 1.9:1) with obstructive tracheobronchial tumours underwent a mean of 2.4 cryosurgical treatments. Their TNM staging was, stage II 6.7%, IIIa 21.0%, IIIb 23.9%, IV 48.4%. Improvement in symptom quantification was found with 76.4, 69.0, 59.2, and 42.6% of symptomatic patients for haemoptysis, cough, dyspnoea, and chest pain, respectively. Mean values for respiratory function improved from 1.38 to 1.41 litres for FEV1 and 1.91 to 2.04 litres for FVC (p </= 0.0001). Mean performance status improved from 59.6 to 75.2 for Karnofsky scale and 3.04 to 2.20 for the WHO scale and the complication rate was 3.5% of treatments. The Kaplan-Meier median survival was 8.2 months and 1- and 2-year survival 38.4 and 15.9%, respectively. Survival analysis suggested a possible survival advantage over alternative palliative techniques. Endobronchial cryosurgery provides a safe and effective method for the palliation of otherwise inoperable lung cancer. It has advantages over other methods in terms of safety, cost, and a low complication rate. Cryosurgery can be repeated as often as required.

Entities:  

Mesh:

Year:  2004        PMID: 14969682     DOI: 10.1016/j.cryobiol.2003.12.003

Source DB:  PubMed          Journal:  Cryobiology        ISSN: 0011-2240            Impact factor:   2.487


  9 in total

1.  Experimental study on biopsy sampling using new flexible cryoprobes: influence of activation time, probe size, tissue consistency, and contact pressure of the probe on the size of the biopsy specimen.

Authors:  Karl-Josef Franke; Mara Szyrach; Georg Nilius; Jürgen Hetzel; Martin Hetzel; Karl-Heinz Ruehle; Markus D Enderle
Journal:  Lung       Date:  2009-06-23       Impact factor: 2.584

2.  Safety and efficacy study of lung cancer stem cell vaccine.

Authors:  Mao Lin; Shu-Ying Li; Ke-Cheng Xu; Zheng-Ping Liu; Feng Mu; Yuan-Ying Yuan; Xiao-Hua Wang; Ji-Bing Chen; Qiao Li
Journal:  Immunol Res       Date:  2015-05       Impact factor: 2.829

3.  Clinical efficacy of percutaneous cryoablation combined with allogenic NK cell immunotherapy for advanced non-small cell lung cancer.

Authors:  Mao Lin; Shu-Zhen Liang; Xiao-Hua Wang; Ying-Qing Liang; Ming-Jie Zhang; Li-Zhi Niu; Ji-Bing Chen; Hai-Bo Li; Ke-Cheng Xu
Journal:  Immunol Res       Date:  2017-08       Impact factor: 2.829

Review 4.  Malignant central airway obstruction.

Authors:  Lakshmi Mudambi; Russell Miller; George A Eapen
Journal:  J Thorac Dis       Date:  2017-09       Impact factor: 2.895

Review 5.  Experimental cryosurgery investigations in vivo.

Authors:  A A Gage; J M Baust; J G Baust
Journal:  Cryobiology       Date:  2009-10-13       Impact factor: 2.487

6.  Endobronchial cryotherapy facilitates end-stage treatment options in patients with bronchial stenosis: A case series.

Authors:  Gerard J Fitzmaurice; Karen C Redmond; David A Fitzpatrick; Waldemar Bartosik
Journal:  Ann Thorac Med       Date:  2014-04       Impact factor: 2.219

7.  Cryoablation combined with allogenic natural killer cell immunotherapy improves the curative effect in patients with advanced hepatocellular cancer.

Authors:  Mao Lin; Shuzhen Liang; Xiaohua Wang; Yinqing Liang; Mingjie Zhang; Jibing Chen; Lizhi Niu; Kecheng Xu
Journal:  Oncotarget       Date:  2017-05-11

Review 8.  Single-Use and Reusable Flexible Bronchoscopes in Pulmonary and Critical Care Medicine.

Authors:  Elliot Ho; Ajay Wagh; Kyle Hogarth; Septimiu Murgu
Journal:  Diagnostics (Basel)       Date:  2022-01-12

9.  A multicenter randomized controlled trial to assess the efficacy of cancer green therapy in treatment of stage IIIb/IV non-small cell lung cancer.

Authors:  Manqiang Sun; Tian Zhou; Xueni Fang; Dan Wang; Haoyue Pang; Yu Chen; Kaiwen Hu
Journal:  Medicine (Baltimore)       Date:  2020-08-14       Impact factor: 1.817

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.